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Abstract
Background: Diclofenac is one of the oldest anti-inflammatory drugs in use. In addition to its inhibition of cyclooxygenases
(COX), diclofenac potently inhibits phospholipase A2 (PLA2), thus yielding a broad anti-inflammatory effect. Since
inflammation is an important factor in the development of pancreatic tumors we explored the potential of diclofenac to
inhibit tumor growth in mice inoculated with PANCO2 cells orthotopically.
Methodology/Principal Findings: We found that diclofenac treatment (30 mg/kg/bw for 11 days) of mice inoculated with
PANC02 cells, reduced the tumor weight by 60%, correlating with increased apoptosis of tumor cells. Since this effect was
not observed in vitro on cultured PANCO2 cells, we theorized that diclofenac beneficial treatment involved other mediators
present in vivo. Indeed, diclofenac drastically decreased tumor vascularization by downregulating VEGF in the tumor and in
abdominal cavity fluid. Furthermore, diclofenac directly inhibited vascular sprouting ex vivo. Surprisingly, in contrast to
other COX-2 inhibitors, diclofenac increased arginase activity/arginase 1 protein content in tumor stroma cells, peritoneal
macrophages and white blood cells by 2.4, 4.8 and 2 fold, respectively. We propose that the subsequent arginine depletion
and decrease in NO levels, both in serum and peritoneal cavity, adds to tumor growth inhibition by malnourishment and
poor vasculature development.
Conclusion/Significance: In conclusion, diclofenac shows pronounced antitumoral properties in pancreatic cancer model
that can contribute to further treatment development. The ability of diclofenac to induce arginase activity in tumor stroma,
peritoneal macrophages and white blood cells provides a tool to study a controversial issue of pro-and antitumoral effects
of arginine depletion.
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Introduction
Inflammation is highly related to both carcinogenesis and to
progression of tumor growth [1]. Epidemiological studies show
that chronic inflammation predisposes patients to cancer devel-
opment and long-term use of non-steroidal anti-inflammatory
drugs (NSAIDs) reduces the risk of several cancers [2].
Cyclooxygenases (COX-1 and -2) are rate-limiting enzymes in
the production of prostaglandins (PGs) from arachidonic acid.
COX-1 expression is generally constitutive, while COX-2 is
usually induced by stimuli involved in inflammatory responses.
Prostaglandin E2 (PGE2), a primary metabolite of COX-2, has
been shown to promote cell survival, proliferation, and angiogen-
esis and inhibit apoptosis and antitumor immune response, all
processes promoting cancer development [3].
Pancreatic cancer is a lethal disease with very limited options for
treatment. Chronic pancreatitis predisposes individuals to devel-
oping pancreatic ductal adenocarcinoma [4] and pancreatic tumor
stroma is characterized by the variety of inflammatory cells [5]
suggesting the involvement of inflammatory processes in this
cancer. COX-2 is overexpressed in approximately 75% of human
carcinomas including those of the pancreas. Recent studies in
transgenic mice [6,7,8] have shown that COX-2 overexpression in
the exocrine pancreas induced pancreatitis-like-state. The onset of
the cancer in these mice was prevented by maintaining mice on
selective COX-2 inhibitors, further demonstrating the important
role of inflammation on pancreatic cancer development.
Human trials to prevent colon cancer were recently conducted
using COX-2 inhibitors. Despite encouraging results in colon
cancer prevention and reduction in the incidence of colon
adenomas, NSAIDs and selective COX-2 inhibitors can cause
serious cardiovascular and gastrointestinal side effects and
therefore are not routinely recommended for these diseases [9,10].
Diclofenac, one of the oldest NSAIDs has been in use since
1976. Diclofenac inhibits cyclooxygenases non-selectively. Studies
in humans demonstrated that it reduces 94% of COX-2 and 49%
of COX-1 activity [11]. In vitro it potently inhibits phospholipase
A2 (PLA2) [12], the enzyme which liberates arachidonic acid
and lysophospholipid to generate a family of pro-inflammatory
eicosanoids (including PGE2) and platelet activating factor.
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vivo. PLA2 is believed to play a key role in the first steps of the
inflammatory cascade leading to acute pancreatitis [12]. The
initial study [13], followed by several other groups, has shown that
diclofenac can significantly decrease the rate of acute pancreatitis
caused by endoscopic retrograde cholangiopancreatography.
In light of diclofenac ability to inhibit potently both COX-2 and
PLA2 we have explored its anticancer potential in a mouse model
of pancreatic cancer. Here we report that diclofenac treatment
causes a 60% decrease in tumor size. This is due to increased
apoptosis of tumor cells. We provide evidence that this effect is
indirect and operates through at least two mechanisms. First,
diclofenac yields a significant antiangiogenic effect, as demon-
strated by a strong reduction in vascular endothelial growth factor
(VEGF) tumor content, decreased microvascular density and
morphological changes in tumor blood vessels. Second, diclofenac
treatment remarkably increases arginase activity in tumor stroma
cells, peritoneal macrophages and white blood cells. This is an
unexpected finding since COX-2 inhibitors were shown to reduce
tumor growth through arginase inhibition [14,15] Our results are
in line with earlier studies, which point to antitumoral [16] and
antiangiogenic effect [17] of arginine depletion and support the
rather controversial approach of anticancer treatment by enhanc-
ing arginase activity [18,19].
Methods
Ethics statement
Experimental animal procedures were approved by the Ethical
Committee of the Hebrew University, which acts under the
surveillance of the AAALAC International.
Animals and PANCO2 cell line
Female CB6F1 mice (9–10 weeks old) and male Sprague-
Dawley rats (200 g) were from Harlan, Israel. Female
CX3CR1
GFP/+ mice [20] were generously provided by S. Jung
(Rehovot, Israel). In these mice a GFP reporter is driven by the
CX3CR1 promoter. Activity of this chemokine receptor promoter
is restricted to mononuclear myeloid cells, including all circulating
CD116
+ monocytes, and is essentially absent from cells of the
lymphoid lineage. All experiments except the experiment
presented in Fig S3 were performed using CB6F1 mice.
PANC02 cells were a generous gift from M Dauer (Munich,
Germany). Cells were maintained in RPMI with 10% fetal bovine
serum (FBS), 2 mM L-glutamine, 100 U/ml penicillin and
100 mg/ml streptomycin.
Orthotopic-syngeneic model of pancreatic cancer
Mice were anesthetized with a mixture of ketamine-xylazine.
The pancreas was injected with 4610
5 (CB6F1 mice) or 6610
5
(CX3CR1
GFP/+ mice) PANC02 cells in 30 ml phosphate buffered
saline (PBS). Mice were removed from an experiment if a
peritoneal leakage was suspected. Sham operated mice under-
went the same procedure and were injected with 30 ml PBS. Mice
were divided into groups of 6 to 8 animals per group. The treated
group received 30 mg/kg b.w. diclofenac in drinking water
starting from day 3 after inoculation. The dosage was calculated
based on the estimate that a mouse drinks about 3 ml water per
day. Mice were killed 14 days after inoculation unless specified
otherwise.
Blood for white blood cells (WBC) preparation, VEGF and
nitrogen oxide (NO) concentration was taken from heart.
Peritoneal cavity was flushed with 2 ml of PBS with 0.1% bovine
serum albumin (BSA) for macrophages preparation, for measure-
ment of VEGF and for NO concentrations.
Peritoneal cells and peritoneal macrophages isolation
Peritoneal cells were obtained by centrifugation of peritoneal
cavity flush. Peritoneal macrophages were isolated from peritoneal
cells by differential adhesion to plastic. The macrophages were
cultured in RPMI with 10% FBS, 2 mM L-glutamine, 100 U/ml
penicillin and 100 mg/ml streptomycin for 20 hrs. To measure
arginase activity, cells were washed with PBS and dissolved in
0.1% TritonX100 in water for 30 min at room temperature.
Tumor homogenates
Tumor homogenates were prepared from tumor samples which
were stored at 280uC, in water containing 0.1% Triton X 100
and protease inhibitor cocktail (Sigma P8340). Homogenates were
centrifuged for 30 min at 13400 g and the supernatants were used
for measuring arginase activity, arginase 1, smooth muscle actin
and VEGF content and caspase-3 activation.
Bone marrow cells isolation
Tibias and femurs of tumor bearing mice were removed and
flushed with PBS. After centrifugation of harvested cells on a Ficoll
gradient at 4000 g for 20 min at room temperature mononuclear
cells were isolated with PE-conjugated primary antibody anti–CD
115 and anti-PE microbeads (Biolegends). CD-115 positive and
negative cells were analyzed for arginase activity.
White blood cells isolation (WBC)
WBC were isolated using Ficoll density gradient (Amersham).
WBC fraction was washed, cells were counted, lysed in water
containing 0.1% Triton X 100 and analyzed for arginase 1 protein
content.
Aortic ring sprouting assay
Aortic rings were prepared from thoracic aortas of Sprague-
Dawley rats, as described [21]. Rings were embedded in collagen
gel and maintained in Bio MpM medium (Biological Industries,
Israel). The treatment with 10 mM diclofenac started one day after
seeding and lasted for 5 days. Rings were then fixed in 4%
buffered formalin, stained with 0.02% crystal violet in absolute
ethanol. Sprouting area was evaluated using the Image Pro
program.
Caspase-3 activation
Caspase-3 activation was measured in tumor homogenates by
separating the non-cleaved and cleaved caspase-3 on a 20%
acrylamide SDS-PAGE electrophoresis gel and blotting with
monoclonal anti–caspase-3 (Cell Signaling).
VEGF and NO content
VEGF content was measured in serum, in supernatant of
peritoneal cavity flush, in tumor homogenates, PANC02 and
cultured macrophages using the mouse VEGF Quantikine
immunoassay kit (R &D systems).
NO content was measured in the serum and in the supernatant
of peritoneal cavity flush using a nitrate/nitrite colorimetric assay
kit (Cayman Chemical Company).
Arginase activity
Arginase activity was measured as described [22]. 100 mgo f
protein was assayed for 10 min at 37uC for peritoneal cells and
macrophages, 30 min for tumor homogenates and 2 hours for
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using the micro BCA protein assay kit (Thermo Scientific).
Arginase 1 and smooth muscle actin protein content
Proteins from tumor homogenates, WBC lysates and GFP
positive cells isolated from tumors were separated on 10%
acrylamide SDS-PAGE electrophoresis gel and blotted either with
monoclonal arginase-1(BD Transduction Laboratories) or mono-
clonal smooth muscle actin (Sigma).
Isolation of mononuclear myeloid cells from tumors
Tumors were extracted from CX3CR1
GFP/+ mice and digested
with collagenase (400 units/ml; Sigma and Dnase 0.33 mg/ml;
Sigma) for 45 min at 37uC. GFP positive population was purified
by high speed cell sorting using FACS Aria (Becton, Dickinson).
Cells were counted and lysed in water containing 0.1% Triton X
100 and analyzed for arginase 1 protein content.
PANCO2 cells rate of growth
PANC02 cells were seeded in RPMI supplemented with 10%
FBS, 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml
streptomycin. Diclofenac (10 or 50 mM) was added the following
day and after 4 days of treatment, cells content was measured
using a cell proliferation kit (Biological Industries, Israel).
Immunohistochemistry, TUNEL staining and
morphometry
Paraffin sections of tumors were stained using the following
primary antibodies: rat anti-mouse F4/80 (Serotec), monoclonal
anti- arginase-1(BD Transduction Laboratories), monoclonal anti-
a-smooth muscle actin (Sigma), monoclonal anti- Ki 67 (Neo-
markers), rabbit anti- phosphor-histone H3 (Cell Signaling), rabbit
anti-VEGF (Calbiochem) and monoclonal anti- von Willebrandt
factor (DACO). Horseradish peroxidase (HRP) conjugated
secondary antibodies were used for chromogenic detection.
TUNEL staining [23] was performed using in situ cell death
detection kit (Roche).
Quantification of immunostaning data was performed either by
high power field analysis counting of at least 10 areas/slide of 4
different tumors in each group or with the aid of image analysis
system (Ariol SL-50).
Statistical analysis
All data were analyzed with SigmaStat software (Aspire software
international). A Mann-Whitney test was used to calculate
significant differences between untreated and diclofenac treated
samples. A value of p#0.05 was accepted as significant.
Sample size and number of repetitions are indicated in legends.
Results
Diclofenac inhibits tumor growth in an orthotopic model
of pancreatic cancer in mice
PANC02 cells were injected into the tail of the pancreas. After 4
days cancer cells formed small tumors of approximately 4 mm
length. Tumors developed rapidly; at day 8 they had doubled in
length and consistently metastasized to the peritoneal area of the
abdominal incision executed for tumor inoculation. At day 14,
tumors which grew at the site of the inoculation (primary tumors),
weighed 300–500 mg and were highly vascularized. The meta-
static tumors at the abdominal cut and in spleen were also
prominent (Fig 1A).
Three to four weeks after inoculation, the peritoneal cavity was
full of bloody ascites. Numerous metastatic tumors were found in
the peritoneal cavity, including lymph nodes of the alimentary
track, and mice began to die. Metastatic tumors on liver or lungs
were not detected.
Subsequent experiments were therefore terminated at day 14
after inoculation. The mice appeared normal at this stage and
there was no loss of body weight.
Diclofenac (30 mg/kg bw) was given daily in drinking water
starting at day 3 after inoculation. Its effects were examined after
11 days of treatment. As shown in Fig 1B, the weight of the
primary tumor (growing in the pancreas) was significantly lower
(60%) in diclofenac treated mice as compared to untreated
animals. Metastatic tumors which grew in the abdominal cut also
weighed less in diclofenac treated mice, in all experiments, yet this
effect did not achieve statistical significance.
Diclofenac increases apoptosis of tumor cells in vivo, but
not in vitro
The decreased tumor weight observed in diclofenac treated
mice led us to examine proliferation and apoptosis of tumor cells.
Tumors stained for Ki 67 (present during all active phases of the
cell cycle: G1, S, G2, and mitosis) and of phospho-histone H3 (the
specific marker of mitotic cells) showed no difference between
untreated and diclofenac treated mice, Fig S1.
However, as shown in Fig 2, diclofenac treatment increased
apoptosis by 6 fold, as indicated by TUNEL staining of tumors
and quantification (Fig 2A). This finding was further supported by
an enhanced presence of cleaved caspase 3 in homogenates from
tumors excised from diclofenac treated mice (Fig 2B).
The enhanced apoptosis caused by diclofenac in vivo could not
be recapitulated in vitro. PANC02 cells cultured for 4 days in the
presence of 10 and 50 mM of diclofenac grew at the same rate as
untreated cells (Fig 2C) indicating that the in vivo effects of
diclofenac require some mediators that are absent in the in vitro
system.
Antiangiogenic effect of diclofenac in vivo and ex vivo
Tumors from diclofenac treated animals were very pale (Fig 1A),
suggesting that the treatment caused an antiangiogenic effect.
Indeed, as shown in Fig 3A and B, staining for vascular endothelial
marker von Willebrand Factor and counting of blood vessels
revealed a 4 fold drop in the number of large peripheral vessels
and a 2 fold drop in capillary density in tumors of diclofenac
treated mice. Furthermore, smooth muscle actin staining (Fig 3C)
revealed thin, straight vessels in treated tumors when compared to
numerous, wide, tortuous blood vessels from tumors of untreated
mice. Analysis of smooth muscle actin expression in tumor
homogenates by western blot showed a significant decrease (2.5
fold) in diclofenac treated mice (Fig 3D and E).
VEGF has been shown to be the major proangiogenic factor in
tumors [24]. Therefore, we measured tumor VEGF levels of
diclofenac treated and untreated mice (Fig 3F). Treated mice
tumors contained 3 times less VEGF when compared to tumors
from untreated mice, suggesting that the decline in tumor
vasculature results from a down regulation of VEGF (Fig 3F,
top). Since tumor cells rapidly spread through the abdominal
cavity, we next measured VEGF content in the peritoneal fluid.
The flushable quantity of VEGF from the peritoneal cavity of
tumor- bearing mice was 13 times higher than sham-operated
healthy mice. This amount decreased by 2.8 fold after diclofenac
treatment (Fig 3F, center).
These pronounced effects on VEGF content, both in peritoneal
cavity and in tumor tissue, were not reflected in any changes in
Diclofenac and Cancer
PLoS ONE | www.plosone.org 3 September 2010 | Volume 5 | Issue 9 | e12715VEGF serum concentration (Fig 3F, bottom). Thus, serum VEGF
concentrations were similar in serum of healthy-sham operated
mice, in tumor- bearing mice and in tumor-bearing mice treated
with diclofenac.
To determine whether diclofenac can directly inhibit angio-
genesis, we measured sprouting angiogenesis of rat aortic rings ex
vivo in response to drug treatment. As shown in Fig 3G, sprouting
area was inhibited by 2.5 fold, when aortic rings were incubated
with 10 mM of diclofenac (C max of diclofenac-treated patients),
thus showing that diclofenac can directly inhibit blood vessel
development.
Diclofenac increases arginase activity in pancreatic
tumors and in peritoneal macrophages, but not in bone
marrow-CD 115 positive and CD 115 negative cells
One of the results of COX-2 overexpression by tumor cells is a
large production of PGE2 which leads to an impaired T-cell
response [14] [25]. PGE2 induces arginase 1 activity and arginine
uptake in myeloid derived suppressor cells (MDSCs), thus causing
arginine depletion in the tumor surrounding. The relative lack of
arginine causes a defect in the CD3f expression of the tumor-
infiltrating T cells. Since COX-2 inhibitors were shown to partially
stop tumor growth through arginase inhibition in MDSC [14,25]
we measured arginase activity in pancreatic tumor homogenates
from non-treated and diclofenac treated mice (Fig 4A, top).
To our surprise arginase activity was not inhibited by diclofenac
treatment, but rather was significantly activated by 2.4 fold.
Immuno-histological staining showed arginase 1 positive cells at
the periphery of tumors in both untreated and diclofenac treated
mice (Fig 4B). The number of arginase 1 expressing cells and their
staining intensity seemed to increase under diclofenac treatment. A
significant, 1.8 fold increase in arginase 1 protein content in
tumors of diclofenac treated mice was also measured by western
blot analysis of tumor homogenates (Fig S2). Using an antibody
against the macrophage marker F4/80 (Fig 4C) we could not
detect any overlap with arginase 1 staining.
In order to further characterize the arginase 1 expressing cells in
PANC02 tumors, we inoculated PANC02 cells into transgenic
mice where a GFP reporter is driven by the CX3CR1 promoter.
Activity of this chemokine receptor promoter is restricted to
Figure 1. Diclofenac inhibits primary tumors growth in an orthotopic model of pancreatic cancer in mice. Mice were inoculated with
4610
5 PANC02 cells into the tail part of pancreas. On day 3 after inoculation (the day of inoculation was designated as day 1) mice were randomized
into untreated and diclofenac treated groups (7–8 mice in each group) and diclofenac 30 mg/kg b.w treatment was started. On day 14 after
inoculation mice were killed and primary and metastatic tumors were removed and weighed. A, a representative photographs of in situ primary
(circles) and metastatic tumors (arrows). Inserts show isolated primary tumors. B, Mean 6 SE of tumor weights of 8 untreated and 7 diclofenac treated
mice * P#0.01. The representative experiment out of four is shown.
doi:10.1371/journal.pone.0012715.g001
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+
monocytes, and is essentially absent from cells of the lymphoid
lineage. We isolated GFP positive cells from tumors and found that
these cells express high levels of arginase 1 (Fig S3).
Thus, the increased activity of arginase found in tumors from
diclofenac treated mice is due at least in part to the activation of
arginase 1 in monocyte derived CX3CR1
+ cells. Arginase activity
was absent in cultured PANC02 (results not shown) and arginase 1
protein was never detected in tumor cells in vivo by immunostain-
ing.
The striking effect of diclofenac treatment on arginase activity in
pancreatic tumors led us to examine arginase activity in peritoneal
macrophages. Peritoneal macrophages can be involved in tumor
surveillance [26] and show an enhanced arginase expression in
tumor-bearing mice [27]. Macrophages from peritoneal lavage
were isolated by preferential attachment to culture dishes and
cultured overnight. Immunostaining showed that they were both
F4/80 positive and arginase 1 positive (results not shown).
Arginase activity was upregulated (4.8 fold) in macrophages
derived from tumor- bearing mice treated with diclofenac for 11
days, when compared to untreated mice, (Fig 4A center).
Since macrophage arginase expression can change in response to
culture dish adhesion [28] we also measured arginase activity in
non-cultured freshly isolated cells from the mouse peritoneal cavity,
thereby compromising on macrophages purity, (Fig 4A bottom).
Diclofenac effectively stimulated arginase activity in non-
cultured cells derived from both tumor-free and tumor-bearing
mice treated with diclofenac for 2 days only by 7 and 3 fold,
respectively. Tumor presence enhanced arginase activity by 4 fold
increasing the activity from 0.03 (cells from non-tumor bearing
mice) to 0.12 mg urea/min/mg protein (cells from tumor -bearing
mice) which is in line with previous reported results [27].
We also counted the number of peritoneal cells extracted from
each mouse and found that a 2 day diclofenac treatment yielded a
3 fold increase in cells from tumor-free mice. The mean number of
cells6SE was 0.6610
660.06610
6 extracted from untreated mice
and 1.5610
660.4610
6 from diclofenac treated mice (p#0.02, 7
mice in each group).
This observation shows that after a short diclofenac treatment,
the total arginase activity in peritoneal cells (mostly macrophages)
is extremely high, both because of the large increase in a specific
activity of this enzyme and because of the increase in the number
of activated cells.
The activation of the arginase activity by diclofenac could not
be demonstrated in vitro. Incubation of peritoneal macrophages for
48 hours (Fig 4D) did not increase arginase activity, but rather
yielded a certain decrease in the specific activity of this enzyme.
The same results were obtained when macrophages were
incubated for 96 hours with diclofenac (results not shown). Thus,
similarly to the effect of diclofenac on apoptosis of tumor cells,
Figure 2. Diclofenac increases apoptosis of tumor cells in vivo but not in vitro. A and B, mice were inoculated with PANC02 cells and treated
with diclofenac as described in Figure 1. A, left, TUNEL staining superpositioned over DAPI staining of fixed tumors, right, mean6 SE % of TUNEL
positive nuclei out of DAPI stained nuclei. About 9000 nuclei from tumors of 4 untreated and 4 diclofenac treated mice were counted * P#0.001. B,
Caspase-3 activation in tumor homogenates of 4 untreated and 3 diclofenac treated mice was measured as described in Materials and Methods, one
out of two experiments. C, PANC02 (3000 cells/well) were seeded in 96-NUNC wells. The day after seeding 10 or 50 mM diclofenac was added and
cells were incubated for additional 4 days. The number of cells was measured using a Cell Proliferation Kit. Mean 6SE of OD of 6 wells in each group.
One experiment representative of 3.
doi:10.1371/journal.pone.0012715.g002
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required in order to achieve the induction of arginase activity by
this drug.
We also investigated whether arginase activation by diclofenac
can be detected in bone marrow macrophage precursors. We
isolated mononuclear cells from tibias and femurs of tumor-bearing
mice untreated and treated for 11 days with diclofenac. We found
verylowarginaseactivityinbothCD115
+andCD115
2cells.Thus,
arginase activation by diclofenac happens either in differentiated
macrophages or the mediators needed for promoting diclofenac-
induced- activation of arginase do not reach the bone marrow
compartment.
Diclofenac decreases NO level in peritoneal cavity and in
serum
We next investigated whether the pronounced activation of
arginase in both tumor tissue and in peritoneal macrophages
influenced NO production. Arginase and nitric oxide synthase
(NOS) compete for arginine, which serves as substrate for both
these enzymes. The activation of arginase can therefore lead to
arginine depletion [29] yielding a decrease in NOS activity.
Indeed, our measurements of the NO content in the peritoneal
cavity (Fig 5top), and in the serum (Fig 5bottom ), showed a
significant decrease in NO in both these compartments. The NO
content in the peritoneal cavity was 1.3 fold lower in tumor-
bearing mice treated for 11 days with diclofenac, as compared
with tumor-bearing untreated mice. The effect on serum NO
concentration was even more pronounced and amounted to 3.5
fold drop in diclofenac treated animals.
In order to study the reason for this very high drop in NO
serum concentration we isolated white blood cells (WBC) from
untreated and diclofenac treated mice. We found that diclofenac
treated mice contained 4 fold higher quantity of WBC per
milliliter of blood. The mean number of cells 6SE was
0.26610
660.03610
6 isolated from untreated mice and
1.2610
660.09610
6 from diclofenac treated mice (P#0.001, 3
mice in each group).
The arginase protein level per equal number of cells was
increased 2 fold Fig S4. Thus, arginase activity in diclofenac
treated mice blood is about 8 fold higher as compared to untreated
mice, and may explain a pronounced decrease in NO serum
concentration.
Discussion
In this study we have examined the antitumor potential of
diclofenac in an orthotopic model of mouse pancreatic cancer.
PANC02 cells injected into the tail of the pancreas rapidly
multiplied, formed large local tumors and repeatedly metastasized
primarily to the cut in the abdomen performed for inoculation
(Fig 1). The tendency of tumor cells to implant into a wound is a
concern in cancer surgery [30] and has been studied in animal
models [31]. The pro-tumor factors secreted by wounds may be
responsible for this phenomenon.
Diclofenac treatment caused a significant decrease in the tumor
weight at the primary site of injection. This decrease was due to
enhanced apoptosis of cancer cells (Fig 2). The anti-tumoral
capacity of diclofenac is generally attributed to its direct effect on
tumor cell viability and cell cycle [32,33]. However this effect is
obtained only using very high concentrations of drug in vitro (up to
800 mM). This may not reflect the in vivo situation except for
topical administration of the drug [32].
In our model, the effect on PANC02 growth rate could not be
reproduced in vitro, when cells were incubated either in the
presence of 10 mM diclofenac, the higher range of C max values
of the drug reported in human [34] and mice [35] studies, or in
the presence of 50 mM of the drug. This prompted us to test
the activity of diclofenac on other tumor growth promoting
components.
Antiangiogenic activity of diclofenac was suggested in a model
of subcutaneous implanted colon-26 adenocarcinoma cells, where
the drug was topically applicated [32]. Our study further
demonstrates the antiangiogenic potential of diclofenac in intra
abdominal tumors. We found, that after 11-day treatment,
diclofenac caused a significant decrease in blood content of
tumors as illustrated by their pale appearance (Fig 1), decrease in
blood vessels count and smooth muscle actin content (Fig 3B and
Fig 3C, D and E).
VEGF has been shown to be the main angiogenic factor in
tumor vascularization. Therefore we measured VEGF protein
levels both in the tumor and in the peritoneum and found a
pronounced decrease in diclofenac treated animals (Fig 3F). The
decrease in VEGF content in tumors of diclofenac treated mice
may be due to a decrease in VEGF expression in tumor cells, in
stroma cells, or in both types of cells. The decrease in the
peritoneal cavity can be due to the change in VEGF content of
tumor or to the direct effect of diclofenac on peritoneal mesothelial
cell lining. Additional studies are required to resolve this issue. The
effect of diclofenac on VEGF production could not be recapitu-
lated in vitro when cultured PANC02 or peritoneal macrophages
were incubated with diclofenac (Fig S5). Previously, diclofenac has
been reported to decrease mRNA-VEGF levels via COX
inhibition in cultured esophageal cancer cell lines [36]. In our in
vivo model it is thus likely that the direct effect of diclofenac on
VEGF production leads to an antiangiogenic effect which in turn
affects apoptosis of cancer cells in the growing tumor.
We have also tested the possibility that diclofenac may directly
affect vascular cells. While diclofenac was unable to induce pro-
apoptotic and anti-VEGF effect on cultured PANC02, its
antiangiogenic effect could be demonstrated ex vivo (Fig 3G).
Figure 3. Diclofenac decreases angiogenesis. A–F, mice were inoculated with PANC02 cells and treated with diclofenac as described in Figure 1.
A–D, diclofenac treatment causes morphological changes in tumor blood vessels. A,Von Willebrand staining of large peripheral vessels (top) and
capillaries (bottom). B, Mean6 SE of large peripheral vessels/slide. counted around the periphery of each slide (top) and mean6 SE of capillaries/area
counted in 10 different central areas of tumors under X40 magnification (bottom). Vessels count was evaluated in tumors of 4 untreated and 4
diclofenac treated mice, * P#0.01. C, smooth muscle actin staining revealed very thin blood vessels walls in diclofenac treated mice. D and E, smooth
muscle actin protein content in tumor homogenates (50 mg protein loaded per lane) of 4 untreated and 3 diclofenac treated mice measured as
described in Materials and Methods, mean 6 SE of arbitrary units/lane, * P#0.01. F, Diclofenac reduces VEGF content of the tumor and the peritoneal
cavity but not the serum. VEGF levels were measured as described in Materials and Methods in the tumor homogenates-pg/mg protein (top), in the
peritoneal cavity-pg/mouse (center) and in the serum-pg/ml (bottom). The results are mean 6 SE of 4 to 6 mice per group. *, ** and # significantly
different from untreated, tumor bearing mice P#0.02. Similar results were obtained in two independent experiments. G, Diclofenac inhibits vascular
sprouting. The ex vivo inhibitory effect of diclofenac on sprouting was measured in rat aortic rings grown in the absence or the presence of 10 mM
diclofenac for 5 days as described in Materials and Methods. The results are mean6 SE of the sprout area of 5 rings in each group measured using the
Image Pro program. * significantly different from untreated group P#0.01 The photographs of representative rings from untreated (left) and
diclofenac (right) treated groups are included. Similar results were obtained in 4 independent experiments.
doi:10.1371/journal.pone.0012715.g003
Diclofenac and Cancer
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rings, it yielded a pronounced inhibition of sprouting. This
suggests that diclofenac can directly inhibit the development of
endothelial/smooth muscle cells.
Interestingly, we have found that peritoneal concentration of
VEGF is significantly higher than that of the serum, both in
tumor-free and in tumor-bearing mice. Assuming that the volume
of the peritoneal fluid is about 100 ml [37], our results demonstrate
that the VEGF concentration amounts to about 340 pg/ml in
sham-operated-tumor-free mice and to above 4000 pg/ml in
tumor-bearing mice. The high concentration of VEGF in the
peritoneal cavity does not equilibrate with the blood compartment
and is 4 and 55 fold higher (as compared with serum values) in
sham-operated and tumor-bearing mice, respectively. In healthy
pigs [38] it was also shown that the intra peritoneal VEGF does
not equilibrate with the serum. Our results, as well as study [39],
challenge the notion that systemic VEGF levels can predict tumor
load. Furthermore it may be interesting to explore the possibility of
delivering antiangiogenic antibodies for intra abdominal tumors
directly into the peritoneal cavity and not systemically.
Unlike the clear antineoplastic effect of diclofenac through
inhibition of angiogenesis, the striking activation of arginase
activity (Fig 4), both in tumor stroma and in peritoneal
macrophages is difficult to assess in context of pro- or anti-cancer
Figure 4. Diclofenac enhances arginase activity in tumors, peritoneal cultured macrophages and in freshly isolated peritoneal cells,
but only when introduced in vivo and not in vitro. A–C, all mice except those indicated were inoculated with tumors on day 1 and killed on day
14. A, arginase activity was measured as described in Materials and Methods in tumor homogenate (top), in macrophages isolated by peritoneal
cavity flush and cultured for 20 hrs (center), and in freshly isolated peritoneal cells (bottom). Mice were treated with diclofenac 30 mg/kg for 11 days
(top and center) or for 2 days before the end of the experiment (bottom). The results are mean6 SE of arginase activity in tumor homogenates of 6–7
mice in each group (top) or in Triton X-100 dissolved cells obtained from 3–7 mice through peritoneal flush and measured in quadruplicates (center
and bottom). Each experiment was repeated at least 3 times and the results of the representative experiment are shown. * significantly different from
untreated group P#0.01. # significantly different from untreated group of tumor- free- mice. B, arginase-1 staining of tumors. Fixated tumors were
stained for arginase 1 as described in Materials and Methods. Photographs of sections were taken under X 10 (top) or X 40 (bottom) magnification.
C, The identification of two separate populations of cells in tumor (diclofenac-treated) stroma: F4-80 positive and arginase positive cells. The serial
sections were stained for F4/80 (left) and for arginase 1, (right). The same areas were identified and compared for the presence of both markers.
Photographs of sections were taken under X 20 magnification. One experiment, representative of 2. D, Diclofenac does not induce arginase activity
when incubated with macrophages in cell culture. Peritoneal macrophages were isolated from tumor-free mice as described in Materials and
Methods and incubated for 48 hours with 10 or 30 mM diclofenac followed by arginase measurement. Mean 6SE of arginase activity of 3 wells in
each group. One experiment, representative of 3.
doi:10.1371/journal.pone.0012715.g004
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myeloid derived suppressive cells (MDSC), was associated with
immunosuppressive activity and tumor-promotion [25]. The
authors proposed that high COX-2 activity of tumor cells releases
PGE2, which activates arginase in MDSC and leads to
extracellular arginine depletion and subsequent T-cell dysfunction.
Along with these results, two additional studies [14,15] have
shown that treatment of tumor bearing mice with COX-2 specific
inhibitors completely blocked the induction of arginase activity,
reduced MDSC accumulation and decreased tumor growth.
However, there is evidence that tumor cells are particularly
sensitive to arginine depletion [40] and that enhanced arginase
activity can restrict tumor growth [18] and [16]. Furthermore it
has been shown that dietary arginine restriction caused a
significant reduction in both tumor incidence and tumor
multiplicity in a mouse papilloma cancer model [41].
To our knowledge we are the first to show that diclofenac causes
pronounced arginase activation in tumor stroma CX3CR1
+ cells, in
peritoneal macrophages and in WBC. This activation correlates with
a significant inhibition of tumor growth. Further research isneeded in
order to determine if this correlation is causative or coincidental.
Our study supports the development of a new therapeutic avenue
through the use of pegylated recombinant human arginase [18,19].
Supporting Information
Figure S1 Diclofenac does not affect proliferation. Mice were
inoculated with PANC02 cells and treated with diclofenac as
described in Figure 1. Ki 67 and phosho-histone H3 staining of
fixed tumors was performed as described in Materials and
Methods. Ki 67 was quantified (% of Ki positive nuclei) with aid
of image analysis system (Ariol SL-50). The number of phospho-
histone H3 positive cells/area was quantified by counting 10
different areas under X 20 magnification. Evaluations were
performed in tumors of 4 untreated and 4 diclofenac treated mice.
Found at: doi:10.1371/journal.pone.0012715.s001 (4.54 MB TIF)
Figure S2 Diclofenac increases arginase 1 protein content in
tumor homogenates. Mice were inoculated with PANC02 cells
and treated with diclofenac as described in Figure 1. Tumor
homogenates from 5 untreated and 6 diclofenac treated mice were
prepared and arginase 1 protein content was analyzed using
Western blott as described in Materials and Methods. Mean6SE
of arbitrary units/lane. 50 mg protein of tumor homogenate was
loaded per lane. * significantly different from the untreated group
P#0.001.
Found at: doi:10.1371/journal.pone.0012715.s002 (0.17 MB TIF)
Figure S3 Arginase 1 positive cells are of mononuclear myeloid
cells origin (CX3CR1 positive). PANC02 cells were inoculated
into CX3CR1
GFP/+ mice. After 14 days tumors were extracted,
digested and GFP positive and negative cells were isolated by high
speed cell sorting using FACS, as described in Materials and
Methods. 400 000 cells GFP positive and negative cells were
counted, lysed and analyzed for arginase 1 protein content as
described in Materials and Methods.
Found at: doi:10.1371/journal.pone.0012715.s003 (0.09 MB TIF)
Figure S4 Diclofenac increases WBC arginase 1 content. CB6F1
mice (tumor-free) were treated for 6 days with 30 mg/kg b.w.
diclofenac. WBC were isolated from 1 ml of blood using Ficoll
density gradient as described in Materials and Methods and
counted. 200 000 cells were lysed and analyzed for arginase 1
protein content. Mean6 SE of arbitrary units/lane of 3 untreated
and 3 diclofenac treated mice. *significantly different from the
untreated group P#0.05.
Found at: doi:10.1371/journal.pone.0012715.s004 (0.19 MB TIF)
Figure S5 Diclofenac does not affect VEGF production in
PANC02 or macrophages in vitro. A, PANC02 (3000 cells/well)
were seeded in 962NUNC wells. The day after seeding 10 or
50 mM diclofenac was added and cells were incubated for
additional 4 days. B, Peritoneal macrophages were isolated from
tumor2free mice as described in Materials and Methods and
incubated for 48 hours with 10 or 50 mM diclofenac. At the end of
the incubation cells were washed, lysed and measured for VEGF
content as described in Materials and Methods. Mean6 SE of
pgVEGF/mg protein in 6 wells of untreated and diclofenac
incubated cells.
Found at: doi:10.1371/journal.pone.0012715.s005 (0.17 MB TIF)
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Figure 5. Diclofenac decreases NO content in peritoneal cavity
and in serum. Tumor bearing mice, untreated and treated with
diclofenac 30 mg/kg b.w. for 11 days were sacrificed on day 14 after
tumor inoculation. The peritoneal cavity was flushed and blood was
collected by heart puncture. The results are mean6 SE of NO content in
peritoneal cavity (top) and serum (bottom) of 7–9 mice in each group. *
significantly different from the untreated group P#0.01.
doi:10.1371/journal.pone.0012715.g005
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